SG11201804589TA - Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists - Google Patents

Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists

Info

Publication number
SG11201804589TA
SG11201804589TA SG11201804589TA SG11201804589TA SG11201804589TA SG 11201804589T A SG11201804589T A SG 11201804589TA SG 11201804589T A SG11201804589T A SG 11201804589TA SG 11201804589T A SG11201804589T A SG 11201804589TA SG 11201804589T A SG11201804589T A SG 11201804589TA
Authority
SG
Singapore
Prior art keywords
international
formyl peptide
rule
receptor
receptor agonists
Prior art date
Application number
SG11201804589TA
Inventor
Nicholas R Wurtz
Pravin Sudhakar Shirude
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of SG11201804589TA publication Critical patent/SG11201804589TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -' Organization International Bureau res., 00) (43) International Publication Date ..... ..sr ,„,„.1 15 June 2017(15.06.2017) WIPO I PCT ID Hit (10) WO 111111111111111111IIIIIIII International II III 2017/100390 IIIIIIIIIIIIIII Publication IIIIIIIIIIIIIIIMIIIIIII Number Al IIIIIIII (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, C07D 211/76 (2006.01) A61P 9/10 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, A61K 31/45 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (21) International Application Number: KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, PCT/US2016/065504 MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, (22) International Filing Date: NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, 8 December 2016 (08.12.2016) RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (25) Filing Language: English ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 62/265,885 10 December 2015 (10.12.2015) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: BRISTOL-MYERS SQUIBB COMPANY TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, [US/US]; Route 206 and Province Line Road, Princeton, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, New Jersey 08543 (US). LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, (72) Inventors: WURTZ, Nicholas R.; c/o Bristol-Myers SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Squibb Company, 311 Pennington-Rocky Hill Road, Pen- nington, New Jersey 08534 (US). SHIRUDE, Pravin Sud- Declarations under Rule 4.17: haker; c/o Syngene International Limited, Biocon Special as to applicant's entitlement to apply for and be granted a Economic Zone, Biocon Park, Plot No. 2&3, Bommas- patent (Rule 4.170) Industrial Area IV Phase, Jigani Link Road, Bom- andra masandra, Karnataka, Bangalore 560 099 (IN). — as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) (74) Agents: EPPERSON, James et al.; Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, — of inventorship (Rule 4.17(iv)) New Jersey 08543 (US). Published: (81) Designated States (unless otherwise indicated, for every _ with international search report (Art 21(3)) kind of national protection available): AE, AG, AL, AM, (54) Title: PIPERIDINONE FORMYL PEPTIDE 2 RECEPTOR AND FORMYL PEPTIDE 1 RECEPTOR AGONISTS Il H .4t 1 - Ar N en O O 1-1 It-- 1-1 (57) : The disclosure relates to compounds of foiinula O peptide 1 (FPR1) receptor agonists. The disclosure also provides for the treatment of atherosclerosis, heart failure, chronic obstructive 0 I, ,,Ar3 NAr 2 \ -j ,„, ( I ) x which are formyl peptide 2 (FPR2) receptor agonists and/or foiinyl compositions and methods of using the compounds, for example, pulmonary disease (COPD), and related diseases.
SG11201804589TA 2015-12-10 2016-12-08 Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists SG11201804589TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562265885P 2015-12-10 2015-12-10
PCT/US2016/065504 WO2017100390A1 (en) 2015-12-10 2016-12-08 Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists

Publications (1)

Publication Number Publication Date
SG11201804589TA true SG11201804589TA (en) 2018-06-28

Family

ID=57590898

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201804589TA SG11201804589TA (en) 2015-12-10 2016-12-08 Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists

Country Status (14)

Country Link
US (2) US10717708B2 (en)
EP (1) EP3414227B1 (en)
JP (1) JP6811241B2 (en)
KR (1) KR102772801B1 (en)
CN (1) CN108368046B (en)
AU (1) AU2016366211B2 (en)
BR (1) BR112018011046A2 (en)
CA (1) CA3007972A1 (en)
EA (1) EA034227B1 (en)
ES (1) ES2901471T3 (en)
IL (1) IL259791B (en)
MX (1) MX386387B (en)
SG (1) SG11201804589TA (en)
WO (1) WO2017100390A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018005756A (en) * 2015-11-24 2018-08-01 Squibb Bristol Myers Co Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease.
SG11201804589TA (en) 2015-12-10 2018-06-28 Bristol Myers Squibb Co Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
KR102623473B1 (en) * 2017-06-09 2024-01-09 브리스톨-마이어스 스큅 컴퍼니 Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonist
US11180490B2 (en) 2017-06-09 2021-11-23 Bristol-Myers Squibb Company Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists
EP3634956B1 (en) * 2017-06-09 2021-04-07 Bristol-Myers Squibb Company Aryl heterocyclic piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
CN110997652B (en) * 2017-06-09 2023-02-28 百时美施贵宝公司 Piperidinone formyl peptide 2 receptor agonists
PT3762380T (en) * 2018-03-05 2022-01-25 Bristol Myers Squibb Co Phenylpyrrolidinone formyl peptide 2 receptor agonists
AR114383A1 (en) * 2018-03-09 2020-08-26 Gruenenthal Gmbh PIPERIDINS OR PIPERIDONES SUBSTITUTED WITH UREA AND PHENYL
JP7398455B2 (en) 2018-11-26 2023-12-14 ブリストル－マイヤーズ スクイブ カンパニー Pyrazolone formyl peptide 2 receptor agonist
US20220298186A1 (en) * 2019-06-18 2022-09-22 Bristol-Myers Squibb Company Biaryl dialkyl phosphine oxide fpr2 agonists
EP3789378A1 (en) * 2019-09-06 2021-03-10 Grünenthal GmbH Piperidines or piperidones substituted with urea and heteroaryl
WO2022035923A1 (en) * 2020-08-12 2022-02-17 Bristol-Myers Squibb Company Oxopyrrolidine urea fpr2 agonists

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2432369A1 (en) 2000-12-20 2002-08-08 Bristol-Myers Squibb Pharma Company Cyclic derivatives as modulators of chemokine receptor activity
US7678913B2 (en) * 2004-12-07 2010-03-16 Portola Pharmaceuticals, Inc. Ureas as factor Xa inhibitors
US20140256685A1 (en) * 2013-03-06 2014-09-11 Allergan, Inc. Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
LT3075726T (en) 2013-11-28 2018-03-26 Kyorin Pharmaceutical Co., Ltd. Urea derivatives or pharmacologically acceptable salts thereof useful as formyl peptide receptor like 1 (fprl-1) agonists
EP3303284B1 (en) 2015-05-27 2020-04-08 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
AR104751A1 (en) * 2015-05-27 2017-08-09 Kyorin Seiyaku Kk DERIVED FROM UREA OR A SALT OF THIS ACCEPTABLE FROM THE PHARMACOLOGICAL VIEWPOINT
MX2018005756A (en) 2015-11-24 2018-08-01 Squibb Bristol Myers Co Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease.
SG11201804589TA (en) 2015-12-10 2018-06-28 Bristol Myers Squibb Co Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
KR102623473B1 (en) 2017-06-09 2024-01-09 브리스톨-마이어스 스큅 컴퍼니 Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonist
US11180490B2 (en) 2017-06-09 2021-11-23 Bristol-Myers Squibb Company Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists
EP3634956B1 (en) 2017-06-09 2021-04-07 Bristol-Myers Squibb Company Aryl heterocyclic piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
CN110997652B (en) 2017-06-09 2023-02-28 百时美施贵宝公司 Piperidinone formyl peptide 2 receptor agonists

Also Published As

Publication number Publication date
EP3414227A1 (en) 2018-12-19
US11530183B2 (en) 2022-12-20
AU2016366211A1 (en) 2018-07-26
KR20180091876A (en) 2018-08-16
EA201891143A1 (en) 2018-11-30
ES2901471T3 (en) 2022-03-22
WO2017100390A1 (en) 2017-06-15
MX2018006635A (en) 2018-08-01
EP3414227B1 (en) 2021-11-24
IL259791A (en) 2018-07-31
JP2018536687A (en) 2018-12-13
US10717708B2 (en) 2020-07-21
MX386387B (en) 2025-03-18
KR102772801B1 (en) 2025-02-24
EA034227B1 (en) 2020-01-20
US20180327358A1 (en) 2018-11-15
JP6811241B2 (en) 2021-01-13
US20200299237A1 (en) 2020-09-24
AU2016366211B2 (en) 2021-06-17
CN108368046B (en) 2022-01-14
CA3007972A1 (en) 2017-06-15
BR112018011046A2 (en) 2018-11-21
CN108368046A (en) 2018-08-03
IL259791B (en) 2021-08-31

Similar Documents

Publication Publication Date Title
SG11201804589TA (en) Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
SG11201804098TA (en) Purinones as ubiquitin-specific protease 1 inhibitors
SG11201808821WA (en) Agonistic antibodies that bind human cd40 and uses thereof
SG11201907840RA (en) Fused imidazo-piperidine jak inhibitors
SG11201907427YA (en) Engineered transferrin receptor binding polypeptides
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201811590RA (en) [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
SG11201810983PA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201907356SA (en) Piperidine-substituted mnk inhibitors and methods related thereto
SG11201807301SA (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
SG11201804758QA (en) Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab
SG11201804934PA (en) Novel Compounds
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201807401RA (en) Therapeutic membrane vesicles
SG11201807912SA (en) Vaccine against rsv
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201806745RA (en) Sulfonylureas and related compounds and use of same
SG11201808708RA (en) Heterocyclic amides useful as protein modulators
SG11201906134YA (en) Tyrosine amide derivatives as rho- kinase inhibitors
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201407579QA (en) Interleukin-2 fusion proteins and uses thereof
SG11201808566WA (en) Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide